There are currently 1048 clinical trials in Portland, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Health & Science University, Oregon Health and Science University /ID# 216891, Providence Portland Medical Center and Providence Saint Vincent Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Northwest Research Center, Portland, Oregon
Conditions: Perennial Allergic Rhinitis (PAR)
Register for Updates
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099
Recruiting
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/28/2024
Locations: Research Site, Portland, Oregon
Conditions: Hepatocellular Carcinoma (HCC)
Register for Updates
Pain Management for Head and Neck Cancer Survivors
NCT05115825
Recruiting
This clinical trial improves an existing pain management program and tests its effect on head and neck cancer survivors. This trial aims to find a better program to improve pain-related physical functioning, mood, and quality of life in a sample of individuals who have undergone treatment for head and neck cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: OHSU Knight Cancer Institute, Portland, Oregon +1 locations
Conditions: Head and Neck Carcinoma
Register for Updates
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
NCT04336722
Recruiting
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.
Gender:
All
Ages:
111 days and below
Trial Updated:
05/27/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Biliary Atresia
Register for Updates
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266
Recruiting
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/27/2024
Locations: Research Site, Portland, Oregon
Conditions: NSCLC
Register for Updates
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
NCT05634499
Recruiting
This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Endometrial Cancer
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/26/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Breast Neoplasms
Register for Updates
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
NCT04677777
Recruiting
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collate... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/26/2024
Locations: Oregon Stroke Center at Oregon Health & Science University (OHSU), Portland, Oregon
Conditions: Acute Ischemic Stroke
Register for Updates
A Study of SGN-EGFRd2 in Advanced Solid Tumors
NCT05983133
Recruiting
This study will test the safety of a drug called SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much SGN-EGFRd2 should be given to participants. Part C will use the dos... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
Register for Updates
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/24/2024
Locations: Research Site, Portland, Oregon +1 locations
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
NCT06081894
Recruiting
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/24/2024
Locations: Providence St. Vincent Medical Center, Portland, Oregon +1 locations
Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484
Recruiting
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Kaiser Permanente Interstate Medical Office Central, Portland, Oregon
Conditions: Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Register for Updates